Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lamivudine hepatitis

Liaw YF, Leung NW, Chang XT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B, Asia Hepatitis Lamivudine Study Group, Gastroenterology 119(1) 172-180... [Pg.344]

The pharmacokinetics and safety profile of lamivudine are described above (see Lamivudine). The more prolonged intracellular half-life in HBV cell lines (17-19 hours) than in HIV-infected cell lines (see above) allows for lower doses, administered less frequently, for hepatitis. Lamivudine can be safely administered to patients with decompensated liver disease. [Pg.1147]

Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA et al, (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 1714-1722... [Pg.23]

In addition to the NRTI lamivudine (3TC) and the NtRTI adefovir dipivoxU and tenofovir disoproxil fumarate (which has been recently licensed for the treatment of chronic hepatitis B), two other nucleoside analogues, that is, entecavir and L-dT (tel-bivudine) (Fig.4aa), have been licensed for the treatment of HBV infections. Two other compounds 3 -Val-L-dC (valtorcitabine) and L-FMAU (clevudine) (Fig. 4aa) are in clinical development for the treatment of HBV infections, and yet two other compounds, that is, racivir and elvucitabine (Fig. 3), yield potential for the treatment of both HBV and HIV infections. [Pg.75]

Drugs such as ribavirin that may directly reduce FIDV replication and specific inhibitors of HBV replication such as lamivudine and adefovir dipivoxU have been tested in combination with IFN-a in patients with chronic hepatitis D. [Pg.227]

Akarca US, Ersoz G, Gunsar F, Karasu Z, Santas E, Yuce G, Batur Y (2004) Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 9 325-334... [Pg.230]

CanbakanB, SenturkH, TabakF, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G (2006) Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis a randomized trial. J Gastroenterol Hepatol 21 657-663... [Pg.231]

Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S, Shiomi S, Koh N, Nishiguchi S (2007) Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res 27 201-207... [Pg.232]

Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH (1998) 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28 1121-1127 Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, Hoofnagle JH (1999a) Lamivudine for chronic delta hepatitis. Hepatology 30 546-549... [Pg.236]

Niro GA, Ciancio A, Tillman HL, Lagget M, OUvero A, Pern F, Fontana R, Little N, Campbell F, Smedde A, Manns MP, Andriulli A, Rizzetto M (2005a) Lamivudine therapy in chronic delta hepatitis a multicentre randomized-controUed pilot study. Aliment Pharmacol Ther 22 227-232... [Pg.238]

Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G (2002) Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients a controlled pilot study. J Hepatol 36 799-804... [Pg.239]

Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC (2005) Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 100 2463-2471... [Pg.239]

Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, Jin LJ, Yang ZJ, Xu YP (2006) Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigennegative Chinese patients and its suppression of lamivudine-resistant mutations, J Antimicrob Chemother 58 1031-1035... [Pg.240]

Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7 428 34 Wong DK, Cheung AM, O Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119 312-323... [Pg.242]

Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (ETC), J Virol 75 4771 779... [Pg.315]

Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, MUler MD, Xiong S (2003) The hepatitis B virus polymerase mutahon rtV 173L is selected during lamivudine therapy and enhances viral repUcation in vitro, J Virol 77 11833-11841... [Pg.315]

Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, di BiscegUe AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B, N Engl J Med 357 2576-2588... [Pg.317]

Warner N, Locamini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T (2007) The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro, Antimicrob Agents Chemother 51 2285-2292... [Pg.320]

See other pages where Lamivudine hepatitis is mentioned: [Pg.343]    [Pg.343]    [Pg.198]    [Pg.200]    [Pg.124]    [Pg.20]    [Pg.75]    [Pg.82]    [Pg.168]    [Pg.231]    [Pg.231]    [Pg.232]    [Pg.235]    [Pg.235]    [Pg.236]    [Pg.236]    [Pg.237]    [Pg.240]    [Pg.242]    [Pg.242]    [Pg.308]    [Pg.323]    [Pg.324]    [Pg.326]    [Pg.326]    [Pg.327]    [Pg.341]    [Pg.341]    [Pg.341]    [Pg.342]    [Pg.342]    [Pg.343]    [Pg.343]    [Pg.343]   
See also in sourсe #XX -- [ Pg.354 ]

See also in sourсe #XX -- [ Pg.86 ]



SEARCH



© 2024 chempedia.info